Let-7 MicroRNA As a Potential Therapeutic Target with Implications for Immunotherapy

Overview

Journal Expert Opin Ther Targets

Publisher Informa Healthcare

Specialty Pharmacology

Date 2018 Oct 18

PMID 30328720

Citations 62

Authors

Maud-Emmanuelle Gilles

Frank J Slack

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNA) are a class of small non-coding RNA that play a major role in various cellular processes by negatively regulating gene expression. In the past decade, miRNA dysregulation has been reported to be closely linked to inflammatory diseases. The immune response modulates cancer initiation and progression; miRNAs including let-7 family members have been shown to act as key regulators of the immune responses in various diseases and cancers. Notably, the let-7 miRNA has been reported to be closely associated with immunity, specifically with Toll-like receptors that mediate cytokine expression during pathogen infection and with the regulation of various other immune effectors. Areas covered: In this review, the authors describe the discovery of let-7 as the starting point of the RNA revolution and highlight let-7 as an efficient tool for cancer and immune therapy. Expert opinion: let-7 miRNA has emerged as a key player in cancer therapy and immune responses and it has potential role as a new immunotherapeutic target. However, while there are challenges regarding miRNA delivery, the exciting emergence of personalized medicine for cancer and immunotherapy could be beneficial for the development of let-7 therapeutics.

Citing Articles

Regulation of innate immune response by miRNAs up-regulated in Stevens-Johnson syndrome with severe ocular complications.

Ueta M, Nishigaki H, Yoshioka H, Kinoshita S, Sotozono C Sci Rep. 2025; 15(1):893.

PMID: 39762541 PMC: 11704206. DOI: 10.1038/s41598-025-85528-8.

Deciphering the role of LOC124905135-related non-coding RNA cluster in human cancers: A comprehensive review.

Eftekhari Kenzerki M, Mohajeri Khorasani A, Zare I, Amirmahani F, Ghasemi Y, Hamblin M Heliyon. 2024; 10(22):e39931.

PMID: 39641053 PMC: 11617737. DOI: 10.1016/j.heliyon.2024.e39931.

Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155.

Qian H, Maghsoudloo M, Jabbarzadeh Kaboli P, Babaeizad A, Cui Y, Fu J Int J Med Sci. 2024; 21(14):2781-2798.

PMID: 39512697 PMC: 11539376. DOI: 10.7150/ijms.102123.

LIN28 upregulation in primary human T cells impaired CAR T antitumoral activity.

Garcia-Rodriguez P, Hidalgo L, Rodriguez-Milla M, Somovilla-Crespo B, Garcia-Castro J Front Immunol. 2024; 15:1462796.

PMID: 39478867 PMC: 11521810. DOI: 10.3389/fimmu.2024.1462796.

An integrative network-based approach to identify driving gene communities in chronic obstructive pulmonary disease.

Marino R, El Aalamat Y, Bol V, Caselle M, Del Giudice G, Lambert C NPJ Syst Biol Appl. 2024; 10(1):125.

PMID: 39461973 PMC: 11513021. DOI: 10.1038/s41540-024-00425-6.

References

Yuan J, Nguyen C, Liu X, Kanellopoulou C, Muljo S . Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis. Science. 2012; 335(6073):1195-200. PMC: 3471381. DOI: 10.1126/science.1216557. View

Pasquinelli A, Reinhart B, Slack F, Martindale M, Kuroda M, Maller B . Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000; 408(6808):86-9. DOI: 10.1038/35040556. View

Zhi L, Yu Y, Li X, Wang D, Wang D . Molecular Control of Innate Immune Response to Pseudomonas aeruginosa Infection by Intestinal let-7 in Caenorhabditis elegans. PLoS Pathog. 2017; 13(1):e1006152. PMC: 5271417. DOI: 10.1371/journal.ppat.1006152. View

Trang P, Wiggins J, Daige C, Cho C, Omotola M, Brown D . Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011; 19(6):1116-22. PMC: 3129804. DOI: 10.1038/mt.2011.48. View

Asirvatham A, Gregorie C, Hu Z, Magner W, Tomasi T . MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol Immunol. 2007; 45(7):1995-2006. PMC: 2678893. DOI: 10.1016/j.molimm.2007.10.035. View

Roush S, Slack F . The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505-16. DOI: 10.1016/j.tcb.2008.07.007. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Thomson J, Newman M, Parker J, Morin-Kensicki E, Wright T, Hammond S . Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006; 20(16):2202-7. PMC: 1553203. DOI: 10.1101/gad.1444406. View

Schulte L, Eulalio A, Mollenkopf H, Reinhardt R, Vogel J . Analysis of the host microRNA response to Salmonella uncovers the control of major cytokines by the let-7 family. EMBO J. 2011; 30(10):1977-89. PMC: 3098495. DOI: 10.1038/emboj.2011.94. View

10.

Karagkouni D, Paraskevopoulou M, Chatzopoulos S, Vlachos I, Tastsoglou S, Kanellos I . DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res. 2017; 46(D1):D239-D245. PMC: 5753203. DOI: 10.1093/nar/gkx1141. View

11.

Teng G, Wang W, Dai Y, Wang S, Chu Y, Li J . Let-7b is involved in the inflammation and immune responses associated with Helicobacter pylori infection by targeting Toll-like receptor 4. PLoS One. 2013; 8(2):e56709. PMC: 3577724. DOI: 10.1371/journal.pone.0056709. View

12.

Park S, Shell S, Radjabi A, Schickel R, Feig C, Boyerinas B . Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007; 6(21):2585-90. DOI: 10.4161/cc.6.21.4845. View

13.

Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A . The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. DOI: 10.1038/35002607. View

14.

Kugel S, Sebastian C, Fitamant J, Ross K, Saha S, Jain E . SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell. 2016; 165(6):1401-1415. PMC: 4892983. DOI: 10.1016/j.cell.2016.04.033. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Marcais A, Blevins R, Graumann J, Feytout A, Dharmalingam G, Carroll T . microRNA-mediated regulation of mTOR complex components facilitates discrimination between activation and anergy in CD4 T cells. J Exp Med. 2014; 211(11):2281-95. PMC: 4203951. DOI: 10.1084/jem.20132059. View

17.

Cheng M, Si Y, Niu Y, Liu X, Li X, Zhao J . High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol. 2013; 87(17):9707-18. PMC: 3754137. DOI: 10.1128/JVI.00802-13. View

18.

Seeger T, Xu Q, Muhly-Reinholz M, Fischer A, Kremp E, Zeiher A . Inhibition of let-7 augments the recruitment of epicardial cells and improves cardiac function after myocardial infarction. J Mol Cell Cardiol. 2016; 94:145-152. DOI: 10.1016/j.yjmcc.2016.04.002. View

19.

Kumar M, Erkeland S, Pester R, Chen C, Ebert M, Sharp P . Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008; 105(10):3903-8. PMC: 2268826. DOI: 10.1073/pnas.0712321105. View

20.

Sempere L, Christensen M, Silahtaroglu A, Bak M, Heath C, Schwartz G . Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007; 67(24):11612-20. DOI: 10.1158/0008-5472.CAN-07-5019. View